Oxybutynin Chloride
Product Images NDC 63629-5484

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Oxybutynin Chloride (NDC 63629-5484). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (54841)

Label for Oxybutynin Chloride ER 10 mg tablets by Bryant Ranch Prepack. The label indicates a package of 30 tablets, includes a reference to Ditropan XL 10 mg, and provides storage instructions at room temperature 20-25°C (68-77°F). The label also has a barcode and a caution to keep drugs out of reach of children.*

FDA Label Image

Chemical Structure (Oxybutynin 01)

Chemical structure of Oxybutynin Chloride, showing the molecular arrangement including the cyclohexyl and phenyl groups, carbonyl and hydroxyl groups, a triple bond, and ethylamine hydrochloride components.*

FDA Label Image

Figure 1 (Oxybutynin 02)

A line graph comparing mean plasma R-Oxybutynin concentration (ng/ml) over 24 hours for two dosing regimens: Oxybutynin Chloride Extended Release (ER) Tablets 10 mg once daily (QD) and Oxybutynin 5 mg three times daily (TID). Concentration fluctuates differently between the two dosing schedules across the time points measured.*

FDA Label Image

Figure 2 (Oxybutynin 03)

A line graph showing mean R-Oxybutynin plasma concentration (ng/mL) over time (hours). The y-axis ranges from 0.0 to 2.0 ng/mL, and the x-axis ranges from 0 to 24 hours. Data points with error bars indicate plasma concentration changes at various time intervals up to 24 hours.*

FDA Label Image

Figure (Oxybutynin 04)

A horizontal bar chart illustrating mean change (±SD) in episodes per week from baseline, comparing Oxybutynin Chloride Extended-Release Tablets and placebo. The x-axis shows change range from -40 to 40 episodes per week. Data points with error bars indicate reduction in episodes for both treatments, with Oxybutynin showing greater improvement than placebo.*

FDA Label Image

Figure (Oxybutynin 05)

A horizontal bar chart showing mean change with standard deviation in episodes per week from baseline for Oxybutynin Chloride Extended-Release Tablets and Oxybutynin. The x-axis ranges from -40 to 40 mean change in episodes per week. Each bar is positioned to indicate a negative mean change, suggesting a decrease in episodes for both treatments.*

FDA Label Image

Figure (Oxybutynin 06)

A bar chart showing the mean change with standard deviation in episodes per week from baseline for Oxybutynin Chloride extended-release tablets compared with Oxybutynin. The x-axis ranges from -40 to 40 episodes per week, with both treatments showing a negative mean change indicating a reduction in episodes.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.